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Abstract
Bisphenol A belongs to a group of environmental pollutants, called endocrine disruptors, whose relations-
hip with various health disorders is becoming increasingly evident. One of these disorders is polycystic 
ovary syndrome (PCOS). This narrative review attempts to define key aspects of both bisphenol A and 
PCOS, as well as to consolidate the current knowledge about them with the aim to establish a solid basis 
for their relationship and implication in health. Different studies point out a possible relationship not only 
between PCOS and exposure to bisphenol A, but also to other diseases that are more prevalent in women 
with this syndrome, such as disorders in hormone regulation or metabolism. It is necessary, however, to 
deepen the knowledge about the relationship between bisphenol A and PCOS in order to provide more 
evidence. To this effect, it would be interesting to develop different epidemiological studies focused on 
strengthening and reaffirming the potential causal association.
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1. Introduction
Endocrine disruptors belong to a heterogeneous 
group of molecules (natural or synthetic) which can 
interfere with the endocrine system. This is becau-
se their phenolic structure can mimic or antagonize 
endogenous steroid hormones (1) and cause diffe-
rent metabolic disorders, even the development of 
hormone-dependent cancers (2).
Bisphenol A is one of the endocrine disruptors 
most frequently found in the environment (3). 
This is mainly due to its increasing industrial use 
in the production of many synthetic materials or 
polycarbonates, among others (4). It is considered 
a ubiquitous compound that can be found in reu-
sable bottles, plastic and metal items used in food 
packaging, toys, medical equipment or even dental 
compounds. In this regard, several studies reported 
that it is present in the air, dust or water, with in-
gestion of contaminated food and water being the 
main route of exposure (5). However, absorption 
through the skin and respiratory system can also 
occur (6). In this line, studies developed by the Cen-
ter for Disease Control and Prevention showed a 
detectable level of bisphenol A in samples of urine, 
amniotic fluid, placental tissue, umbilical cord and 
fetal serum (4). This compound has been detected 
in follicular fluid, suggesting that oocytes would 
have been exposed to this contaminant agent du-
ring the folliculogenesis (1).
On the other hand, PCOS is characterized by a he-
terogeneous presence of anovulation, hyperandro-
genism, polycystic ovarian morphology, metabolic 
dysfunction and infertility (7). In addition, this syn-
drome is associated with sexual and psychological 
problems (8). Thus, it increases the probability of 
having symptoms of depression and/or anxiety (9).
Globally, it is considered the most common and 
heterogeneous endocrine disorder in women of 
child-bearing age (10). Its prevalence is between 6% 
and 21% depending on the diagnostic criteria (11). 
In addition, more than 75% of cases of anovulatory 
infertility are ascribed to PCOS (12).
Although the pathophysiology of the syndrome is 
not clear, an increased prevalence of reproductive 
diseases, a decreased female fertility in recent years, 
and a strong presence in our environment of pollu-
tants capable of altering the proper function of the 
endocrine system, make the role of the environment 
increasingly important (13). Hence, a need arises 
for clarifying the potential relationship between en-
docrine disruptors and the potential reproductive 
disorders that could result from such exposure (3). 
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Therefore, the objective of this narrative review is to 
study the relationship between bisphenol A exposure 
and PCOS because of the growing interest in this topic.
1. What do we know about bisphenol A? 
Bisphenol A (Figure 1) is an industrial compound 
able to mimic the effect of estrogenic hormones. It 
is an endocrine disruptor widely used in the ma-
nufacture of many consumer goods (14). Endocrine 
disruptors are agents that interfere with the synthe-
sis, secretion, transport, binding, action or elimi-
nation of the body’s natural hormones responsible 
for the maintenance of homeostasis, reproduction, 
development and/or behavior (15). Additionally, 
due to the effects shown by bisphenol A in chan-
ging several metabolic pathways in humans, par-
ticularly those related to hormonal regulation of 
reproductive processes, bisphenol A is considered 
a xenoestrogen. Xenoestrogens include compounds 
that modify the synthesis, transport, activity and 
metabolism of endogenous estrogens. Therefore, 
they affect the growth, development and reproduc-
tion of organisms (4, 16).
Bisphenol A was first synthesized by Alexander 
Pavlovich Dianin in 1891. It was recognized as an 
artificial estrogen by the British chemist Charles 
Edward Dodds in 1930. Shortly thereafter, it was 
tested for the prevention of adverse pregnancy out-
comes in women with a history of miscarriage. It 
was not until 1947 when the Food & Drug Adminis-
tration (FDA) approved diethylstilbestrol (2). Sub-
sequently, the industrial use of Bisphenol A began 
in the 1950s. In 2008 its production was estimated 
at about 5.2 million tons worldwide and reached 7.7 
million tons in 2015. The consumption is estimated 
to increase to 10.6 million tons in 2022 (6).
Although the safety of bisphenol A in consumer 
goods is largely guaranteed, several studies con-
ducted over the last twenty years claim that this 
compound is not only widely distributed in the en-
vironment, but also exhibits toxicity even at low do-
ses (4). This is because adverse reactions in humans 
generally result from chronic exposure (5).
This pollutant is commonly found in urine and 
blood samples, confirming the high exposure to 
these chemicals (3). Oral ingestion is the main sour-
ce of exposure in humans, although there are many 
routes of exposure (Figure 2). Evidence has been 
found that bisphenol A can enter food during the 
storage time by prolonged contact with plastic, pa-
per containers or even cans. In addition, processes 
such as washing and heating can stimulate its relea-
se, increasing its concentration in food. It has also 
been shown that bisphenol A can be released from 
feeding bottle materials (4).
These circumstances have encouraged the imple-
mentation of numerous restrictive policies, such as 
Directive 2011/8/EU. This directive prohibits the 
use of bisphenol A in feeding bottles due to the lack 
of knowledge about its adverse effects on the bio-
chemical changes in the brain, the immunomodula-
tory activity, and the risk of developing breast can-
cer (4). In addition, the recommended daily intake 
in Europe has decreased from 50 mg/kg bw/day to 
4 mg/kg bw/day (6).
Since bisphenol A can interact with estrogen re-
ceptors, it can interfere with fertility in women (2) 
by modifying steroidogenesis, folliculogenesis and 
ovarian morphology (3). Furthermore, its exposure 
could be related to alterations in oocyte production 
and adverse effects on human fertility by disrupting 
the synthesis of sex steroid activity (4). Bisphenol A 
is also associated with metabolic diseases such as 
type 2 diabetes, reduced insulin sensitivity, altera-
tions in glucose and lipid metabolism, and increa-
sed risk of cardiovascular disease, among others (5).
2. What do we know about PCOS?
PCOS was first described at the beginning of the 
20th century by Lesnoy in 1928 and by Stein and 
Leventhal in 1935 (17). The diagnostic criteria have 
been modified over time. Moreover, this syndrome 
has become important after the international confe-
rence on PCOS promoted by the National Institutes 
of Health (NIH) in 1990. It was in 2003 when these 
criteria were standardized to the Rotterdam criteria 
for the diagnosis of PCOS (18).
Another important contribution to the syndrome’s 
definition are the Androgen Excess and PCOS So-
ciety’s (AE-PCOS) criteria from 2006 (19). There 
was an attempt to settle and unify the observations 
relevant to the disease on the Evidence-based Me-
thodology Workshop on Polycystic Ovary Syndro-
me from 2012. However, the results did not have a 
great impact. Nowadays, Rotterdam criteria are the 
most widely accepted (20, 21).
PCOS is characterized by a number of signs and 
symptoms (Figure 3). The most frequent are related 
to excessive androgen production, including hirsu-
tism, alopecia and acne. Hair growth is particularly 
typical on the chin, neck, lower face and preauri-
cular area. Excessive hair growth usually occurs on 
the lower back, abdomen, buttocks, perineal area, 
inner thighs, and periareolar area. Ovulatory dys-
function, irregular periods and fertility problems 
are common in women with PCOS (22). Insulin 
resistance and polycystic ovarian morphology can 
also be part of the manifestation of PCOS, althou-
gh they are not strictly necessary for a diagnosis. 
Weight gain and insulin resistance are very com-
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mon, varying the prevalence of insulin resistance 
between 40% and 70% when using alternative mar-
kers (23). The examination of ovarian morphology 
is performed by ultrasonography, which will con-
firm polycystic ovarian morphology when the volu-
me of an ovary is ≥ 10 ml and/or there is an increase 
in antral follicles (7). 
An agreement between the European Society of 
Human Reproduction and Embryology (ESHRE) 
and the American Society for Reproductive Medi-
cine (ASRM) was promoted as a possible solution 
to the difficulties for the standardization of diag-
nostic criteria. According to the agreement, PCOS 
can be diagnosed when two of the three following 
criteria are met: i) clinical or biochemical hyperan-
drogenism; ii) chronic oligomenorrhea and/or ano-
vulation; iii) presence of polycystic ovaries in trans-
vaginal ultrasound scan. These are known as the 
Rotterdam criteria for PCOS diagnosis. There are 
currently four recognized PCOS phenotypes, which 
are defined by different combinations of the syn-
drome’s features. Phenotype 1, also called “comple-
te” PCOS phenotype, includes hyperandrogenism, 
primary ovarian insufficiency (POI), and polycystic 
ovarian morphology. In the rest of the phenotypes, 
however, only two of the three criteria are present: 
phenotype 2 includes hyperandrogenism and POI; 
phenotype 3, hyperandrogenism and polycystic 
ovarian morphology; and phenotype 4, POI and 
polycystic ovarian morphology (7).
In addition to its own characteristics, PCOS is rela-
ted to decreased fertility and complications during 
pregnancy, obesity and dyslipidemia, insulin re-
sistance and type 2 diabetes, metabolic syndrome, 
higher risk of anxiety and depression, higher risk 
of cardiovascular disease (10), and higher risk of en-
dometrial hyperplasia and carcinoma (7).
Despite its unclear pathophysiology, growing evi-
dence suggests that PCOS might be a complex 
multigenetic disorder with strong epigenetic and 
environmental influences (21). Patients with PCOS 
showed alterations in their hypothalamic–pituitary 
axis and follicle sensitivity to hormones, insulin re-
sistance and adipocyte dysfunction (7). PCOS can 
be understood as a state of chronic inflammation at 
a low level, which makes it necessary to adopt a li-
festyle avoiding oxidative stress, acidosis or immu-
ne activation in order to alleviate it (24). 
3. Bisphenol A and Polycystic Ovarian 
Syndrome. What is the evidence?
Since bisphenol A can interact with the endocrine 
system, many research studies have tried to descri-
be its relationship with PCOS. The aim was to dis-
cern the role that bisphenol A plays in PCOS etiolo-
gy. Both in vivo and in vitro experiments (4, 25), as 
well as transversal and longitudinal epidemiologi-
cal studies, have been conducted to study this topic 
(3, 26, 27).
As for the results provided by the epidemiologi-
cal studies, the wide presence of bisphenol A in 
the organism has been observed, being higher in 
women diagnosed with PCOS (3, 26, 27). Based 
on this evidence, the previous exposure to envi-
ronmental pollutants that act as endocrine dis-
ruptors could be a risk factor for developing this 
syndrome (27). Therefore, in the cross-sectional 
study conducted by Zhou et al., a mean concen-
tration of 2.35 ng/ml was detected in the urine 
of women with PCOS, being a higher level than 
the one recorded in other women without this pa-
thology (1). Accordingly, other authors pointed 
out how, when compared to the healthy controls, 
the presence of serum bisphenol A is significantly 
larger in women with PCOS (28).
These studies have not only documented the wi-
despread presence of bisphenol A in the organism, 
but also a significant decrease in the antral follicle 
count, along with lower levels of the anti-Müllerian 
hormone and the follicle stimulating hormone. This 
was associated with a relative decrease in the ova-
rian reserve of the women in the sample (1). Ano-
ther consequence is hyperandrogenism, positively 
correlated with serum total testosterone levels and 
the free androgen index (28, 29). This could be rela-
ted to the stimulation of the cell structure surroun-
ding the follicular antrum. The 17-α-hydroxylase 
enzyme, key in the gonadal steroidogenesis, is de-
regulated (29). However, other studies suggest that 
these alterations, characteristic of PCOS, can also be 
the result of the exposure to other environmental 
pollutants such as brominated diphenyl ethers, or-
ganochlorine pesticides, perfluorinated compounds 
or phthalates (27).
Regarding the rest of the criteria for PCOS diag-
nosis, other cross-sectional studies have shown a 
significantly larger waist-to-height ratio in women 
with higher bisphenol A levels in their urine. This 
justifies a possible tendency to be overweight, in-
sulin level above the reference limit (24.9 mIU/L) 
and a greater resistance to insulin evidenced by 
the homeostasis model assessment (HOMA-IR) 
(5, 29). This same population shows an alteration 
of the lipid profile with moderately elevated total 
cholesterol and triglycerides levels, along with a 
decrease of the high-density lipoprotein (HDL) 
compared to controls. Moreover, an increase in 
the leptin levels was observed. This increment of 
the hormone responsible for regulating the appe-
tite may explain weight gain in women diagnosed 
with PCOS (5).
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In other controlled trials in laboratory, such as in 
vivo and in vitro experiments (4, 25), reproductive 
alterations related to PCOS have also been obser-
ved. Irregular periods, alterations in the ovarian 
development with a decrease in corpus luteum and 
antral follicles, in addition to an increase in atretic 
follicles and the presence of cysts that give name to 
this pathology, have been observed (4, 25).
4. Conclusion
Bisphenol A is a pollutant that is on the rise in the 
industry and seems to have a direct correlation to 
reproductive health. At the same time, PCOS has 
become an increasingly prevalent disease. In gene-
ral, the literature included in this revision suggests 
that bisphenol A may exacerbate the metabolic risk 
in women with PCOS or even be part of their etiolo-
gy due to its ability to interfere with the endocrine 
system. Furthermore, bisphenol A would enhance 
weight gain, hyperinsulinemia and insulin resis-
tance, along with dyslipidemia and hyperandroge-
nism. Due to the lack of studies, it is essential to fur-
ther analyze the impact that this compound could 
have on reproductive health, particularly on PCOS. 
This could result in the implementation of future 
restrictions on its industrial use, thus reducing its 
presence on an environmental level. Consequently, 
it would be appropriate to carry out further epide-
miological studies to assess the impact to a long-
term bisphenol A exposure, enabling the establish-
ment of a more solid causal association.
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Figure 3. PCOS signs and symptoms
Figure 2. Sources of bisphenol A exposure
Figure 1. Molecular structure of bisphenol A
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